Canadian Association of Emergency Physicians Sepsis Guidelines: The optimal management of severe sepsis in Canadian emermency departments

Canadian Journal of Emergency Medicine

Volumn 10, Issue 5, 2008, Pages 443-459

  Green, Robert S ^a,h   Djogovic, Dennis ^b   Gray, Sara ^c   Howes, Daniel ^d   Brindley, Peter G ^b   Stenstrom, Robert ^e   Patterson, Edward ^f   Easton, David ^g   Davidow, Jonathan S ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e ST PAUL S HOSPITAL   (Canada)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g HEALTH SCIENCES CENTRE   (Canada)

^h CAEP Critical Care Interest Group   (Canada)

Author keywords

Emergency medicine; Guidelines; Resuscitation; Sepsis; Septic shock; Severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; DOBUTAMINE; DOPAMINE; ETOMIDATE; FLUDROCORTISONE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; HYPERTENSIVE AGENT; HYPERTENSIVE FACTOR; INOTROPIC AGENT; INSULIN; LACTIC ACID; MILRINONE; NORADRENALIN; PLACEBO; VASOPRESSIN;

ADRENAL INSUFFICIENCY; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIUM CULTURE; BLOOD TRANSFUSION; CANADA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY CARE; EMERGENCY MEDICINE; EMERGENCY PHYSICIAN; EMERGENCY WARD; ENDOTRACHEAL INTUBATION; EVIDENCE BASED MEDICINE; FLUID RESUSCITATION; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INTENSIVE CARE; INVASIVE PROCEDURE; LOW DRUG DOSE; LUNG INJURY; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PEER REVIEW; PRACTICE GUIDELINE; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; TACHYCARDIA; THERAPY DELAY; TREATMENT OUTCOME;

EID: 54949129388     PISSN: 14818035     EISSN: 14818035     Source Type: Journal    
DOI: 10.1017/s148180350001054x     Document Type: Review

References (121)

1. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine levels of evidence (May 2001). Available: www.cebm.net/ levels_of_evidence.asp (accessed March 2008).
2. Strehlow MC, Emond SD, Shapiro NI, et al. National study of emergency department visits for sepsis, 1992 to 2001. Ann Emerg Med 2006;48:326-31,331.e1-3.
3. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 17;348:1546-54.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
5. Lambe S, Washington DL, Fink A, et al. Trends in the use and capacity of california's emergency departments, 1990-1999. Ann Emerg Med 2002;39:389-96.
6. Meggs WJ, Czaplijski T, Benson N. Trends in emergency department utilization, 1988-1997. Acad Emerg Med 1999;6:1030-5.
7. Parkhe M, Myles PS, Leach DS, et al. Outcome of emergency department patients with delayed admission to an intensive care unit. Emerg Med (Fremantle) 2002;14:50-7.
8. Nelson M, Waldrop RD, Jones J, et al. Critical care provided in an urban emergency department. Am J Emerg Med 1998;16:56-9.
9. Varon J, Fromm RE Jr, Levine RL. Emergency department procedures and length of stay for critically ill medical patients. Ann Emerg Med 1994;23:546-9.
10. Svenson J, Besinger B, Stapczynski JS. Critical care of medical and surgical patients in the ED: Length of stay and initiation of intensive care procedures. Am J Emerg Med 1997;15:654-7.
11. Sampalis JS, Denis R, Lavoie A, et al. Trauma care regionalization: a process-outcome evaluation. J Trauma 1999;46:565,79; discussion 579-81.
12. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy-in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
13. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
14. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
15. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
16. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
17. van den BG, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345: 1359-67.
18. Bochud PY, Bonten M, Marchetti O, et al. Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S495-512.
19. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-51.
20. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with blood-stream infection. J Intern Med 1998;244:379-86.
21. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003;31:462-7.
22. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
23. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
24. Rivers EP, McIntyre L, Morro DC, et al. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 2005;173:1054-65.
25. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
26. Rivers E. The outcome of patients presenting to the emergency department with severe sepsis or septic shock. Crit Care 2006; 10:154.
27. Hebert PC, Drummond AJ, Singer J, et al. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 1993;104:230-5.
28. Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637-42.
29. Pinsky MR. Cardiovascular effects of ventilatory support and withdrawal. Anesth Analg 1994;79:567-76.
30. Sugerman HJ, Diaco JF, Pollock TW, et al. Physiologic management of septicemic shock in man. Surg Forum 1971;22:3-5.
31. Turnaoglu S, Tugrul M, Camci E, et al. Clinical applicability of the substitution of mixed venous oxygen saturation with central venous oxygen saturation. J Cardiothorac Vasc Anesth 2001; 15:574-9.
32. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999;27:639-60.
33. Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983;11:839-50.
34. Finfer S, Norton R, Bellomo R, et al. The SAFE study: saline vs. albumin for fluid resuscitation in the critically ill. Vox Sang 2004;07(Suppl 2): 123-31.
35. Bunn F, Alderson P, Hawkins V. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2003; (1):CD001319.
36. Roberts I, Alderson P, Bunn F, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2004;(4):CD000567
37. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004;(4):CD001208.
38. Upadhyay M, Singhi S, Murlidharan J, et al. Randomized evaluation of fluid resuscitation with crystalloid (saline) and colloid (polymer from degraded gelatin in saline) in pediatric septic shock. Indian Pediatr 2005;42:223-31.
39. Vincent JL, Gerlach H. Fluid resuscitation in severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32:S451-4.
40. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39.
41. Holmes CL. Vasoactive drugs in the intensive care unit. Curr Opin Crit Care 2005;11:413-7.
42. Holmes CL, Walley KR. The evaluation and management of shock. Clin Chest Med 2003;24:775-89.
43. Nguyen HB, Rivers EP, Abrahamian FM, et al. Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 2006;48:28-54.
44. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
45. Kuhl DA. Current strategies for managing the patient with sepsis. Am J Health Syst Pharm 2002;02/15(Suppl 1):S9-13.
46. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928-48.
47. De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 2003;31:1659-67.
48. Martin C, Viviand X, Leone M, et al. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-65.
49. Martin C, Papazian L, Perrin G, et.al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826-31.
50. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354-7.
51. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19:151-4,
52. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997;23:282-7.
53. Desjars P, Pinaud M, Potel G, et al. A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987; 15:134-7.
54. Meadows D, Edwards JD, Wilkins RG, et al. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988;16:663-6.
55. Desjars P, Pinaud M, Bugnon D, et al. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989;17:426-9.
56. Hesselvik JF, Brodin B. Low dose norepinephrine in patients with septic shock and oliguria: effects on afterload, urine flow, and oxygen transport. Crit Care Med 1989;17:179-80.
57. Marin C, Eon B, Saux P, et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18:282-5.
58. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopaminerin patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139-43.
59. Kellum JA, Decker M. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-31.
60. Olson D, Pohlman A, Hall JB. Administration of low-dose dopamine to nonoliguric patients with sepsis syndrome does not raise intramucosal gastric pH nor improve creatinine clearance. Am J Respir Crit Care Med 1996;154:1664-70.
61. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
62. Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699-703.
63. Holmes CL, Walley KR, Chittock DR, et al. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Cave Med 2001;27:1416-21.
64. Dufresne RG Jr. Skin necrosis from intravenously infused materials. Cutis 1987;39:197-8.
65. Greenwald RA, Rheingold OJ, Chiprut RO, et al. Local gangrene: a complication of peripheral pitressin therapy for bleeding esophageal varices. Gastroenterology 1978;74:744-6.
66. Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med 2002;30:1899-901.
67. Korénberg RJ, Landau-Price D, Penneys NS. Vasopressin-induced bullous disease and cutaneous necrosis. J Am Acad Dermatol 1986;15:393-8.
68. Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996;24: 525-37.
69. Cohen J, Brum-Buisson C, Torres A, et al. Diagnosis of infection in sepsis: an evidence-based review. Crit Care Med 2004;32:S466-94.
70. Smith-Elekes S, Weinstein MP. Blood cultures. Infect Dis Clin North Am 1993;7:221-34.
71. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 1997;10:444-65.
72. Wilson ML. General principles of specimen collection and transport. Clin Infect Dis 1996;22:766-77.
73. Broder G, Weil MH. Excess lactate: an index of reversibility of shock in human patients. Science 1964;143:1457-9.
74. Bernardin G, Pradier C, Tiger F, et al. Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. Intensive Care Med 1996;22:17-25.
75. Shapiro NI, Howell MD, Talmor D, et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005;45:524-8.
76. Trzeciak S, Dellinger RP, Chansky ME, et al. Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med 2007;33:970-7.
77. Aduen J, Bernstein WK, Khastgir T, et al. The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. JAMA 1994;272: 1678-85.
78. Shapiro N, Howell MD, Bates DW, et al. The association of sepsis syndrome anal organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med 2006;48:583,90, 590.
79. Kumar A, Haery C, Paladugu B, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006;193:251-8.
80. Miner JR, Heegaard W, Mapes A, et al. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at ah urban county medical center. J Emerg Med 2001;21:387-92.
81. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-44.
82. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
83. Bochud PY, Glauser MP, Calandra T. Antibiotics in sepsis. Intensive Care Med 2001;27(Suppl 1):S33-48.
84. Simon D, Trenholme G. Antibiotic selection for patients with septic shock. Crit Care Clin 2000;16:215-31.
85. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
86. Marshall JC, Maier RV, Jimenez M, et al. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S513-26.
87. Moss RL, Musemeche CA, Kosloske AM. Necrotizing fasciitis in children: Prompt recognition and aggressive therapy improve survival. J Pediatr Surg 1996;31:1142-6.
88. Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007;7:855-70.
89. Baillie JK. Activated protein C: Controversy and hope in the treatment of sepsis. Curr Opin Investig Drugs 2007;8:933-8.
90. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis anal a low risk of death. N Engl J Med 2005;353:1332-41.
91. Bernard GR, Margolis BD, Shanies HM, et al. Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 2004;125:2206-16.
92. Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002;6:251-9.
93. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
94. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
95. Keh D, Boehnke T, Weber-Cartens S et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003 02/15;167(4):512-20.
96. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;14:1:47-56.
97. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004;329:480.
98. Annane D, Sebille V, Troche G, et al. A 3-1evel prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45.
99. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
100. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003;31:141-5.
101. Bourne RS, Webber SJ, Hutchinson SP. Adrenal axis testing and corticosteroid replacement therapy in septic shock patients-local and national perspectives. Anaesthesia 2003;58:591-6.
102. Bouachour G, Tirot P, Gouello JP, et al. Adrenocortical function during septic shock. Intensive Care Med 1995;21:57-62.
103. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337: 582-3.
104. Goodman S, Sprung CL, Ziegler D, et al. Cortisol changes among patients with septic shock and the relationship to ICU and hospital stay. Intensive Care Med 2005;31:1362-9.
105. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med 2004;32:S527-33.
106. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. transfusion requirements in critical care investigators, canadian critical care trials group. N Engl J Med 1999; 340:409-17.
107. Fan E, Needham DM, Stewart TE. Ventilatory management of acute lung injury and acute respiratory distress syndrome. JAMA 2005;294:2889-96.
108. Kallet RH. Evidence-based management of acute lung injury and acute respiratory distress syndrome. Respir Care 2004;49: 793-809.
109. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The acute respiratory distress syndrome network. N Engl J Med 2000;342:1301-8.
110. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995;332:27-37.
111. Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24.
112. Hickling KG, Walsh J, Henderson S, et al. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med 1994;22:1568-78.
113. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998;338:347-54.
114. Stewart TE, Meade MO, Cook DJ, et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome, pressure- and volume-limited ventilation strategy group. N Engl J Med 1998;338:355-61.
115. Bidani A, Tzouanakis AE, Cardenas VJ Jr, et al. Permissive hypercapnia in acute respiratory failure. JAMA 1994;272:957-62.
116. Stocker R, Neff T, Stein S, et al. Prone positioning and low-volume pressure-limited ventilation improve survival in patients with severe ARDS. Chest 1997;l 11:1008-17.
117. Jolliet P, Bulpa P, Chevrolet JC. Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome. Crit Care Med 1998;26:1977-85.
118. Gattinoni L, Tognoni G, Pesenti A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001;345:568-73.
119. Papazian L, Gainnier M, Marin V, et al. Comparison of prone positioning and high-frequency oscillatory ventilation in patients with acute respiratory distress syndrome. Crit Care Med 2005;33:2162-71.
120. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
121. Malhotra A. Intensive insulin in intensive care. N Engl J Med 2006;354:516-8.